eilatine has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amiel, A; Einat, M; Fabian, I; Kashman, Y; Lishner, M; Markel, D; Nagler, A; Rudi, A; Yarkorli, S | 1 |
| Amiel, A; Einat, M; Fabian, I; Fejgin, MD; Kashman, Y; Nagler, A; Rudi, A | 1 |
2 other study(ies) available for eilatine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Bone Marrow; Cell Division; Cell Survival; Child; Child, Preschool; Cytarabine; Female; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Phenanthrolines; Tumor Cells, Cultured | 1995 |
Synergistic effects of interleukin-11 with other growth factors on the expansion of hematopoietic progenitors from normal individuals and chronic myeloid leukemia patients resistant to treatment with cytosine arabinoside or eilatin.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-11; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenanthrolines; Stem Cell Factor; Tumor Stem Cell Assay | 1996 |